Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18480778 | COMPOSITIONS AND METHODS FOR TARGETING AND KILLING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSCS) AND TREATING DRUG RESISTANT CANCERS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17928767 | INHIBITION OF BMI1 ELIMINATES CANCER STEM CELLS AND ACTIVATES ANTITUMOR IMMUNITY | Non-Final OA | The Regents of the University of California |
| 19292946 | APPLICATION OF ITIH1 IN PREPARATION OF DRUG FOR TREATMENT OF HEPATOCELLULAR CARCINOMA | Non-Final OA | Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technolog |
| 15734470 | COMPOSITIONS AND METHODS FOR INDUCING PHAGOCYTOSIS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17786442 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | Final Rejection | BRISTOL-MYERS SQUIBB COMPANY |
| 17767035 | COMPOSITIONS AND METHODS FOR TREATING CYTOTOXIC T CELL RESISTANT TUMORS | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 19218323 | IG-LIKE FUSION PROTEINS FOR TREATING GRAVES DISEASE | Final Rejection | CANOPY IMMUNO-THERAPEUTICS LTD. |
| 17153128 | PET RADIOPHARMACEUTICALS FOR NON-INVASIVE EVALUATION OF HIF-2alpha | Final Rejection | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 17129352 | PET RADIOPHARMACEUTICALS FOR NON-INVASIVE EVALUATION OF HIF-2alpha | Final Rejection | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 16317943 | TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH A KINASE INHIBITOR | Final Rejection | The Trustees of the University of Pennsylvania |
| 18025896 | A Scoring Method for an Anti-HER2 Antibody-Drug Conjugate Therapy | Non-Final OA | Daiichi Sankyo Company, Limited |
| 17621909 | PDL1 POSITIVE NK CELL CANCER TREATMENT | Final Rejection | City of Hope |
| 18276823 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | Non-Final OA | DENALI THERAPEUTICS INC. |
| 18357966 | ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME | Final Rejection | SUTRO BIOPHARMA, INC. |
| 18163810 | OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP | Non-Final OA | Bruker Spatial Biology, Inc. |
| 18255043 | COMPOSITIONS AND METHODS FOR RAPID PRODUCTION OF VERSATILE SINGLE DOMAIN ANTIBODY REPERTOIRES | Non-Final OA | The Rockefeller University |
| 18263014 | METHODS OF ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN PATIENTS TREATED WITH VLA-4 ANTAGONISTS | Non-Final OA | UNIVERSITE TOULOUSE III – PAUL SABATIER |
| 18357366 | Anti-Tumor Immunotherapy Enhancer | Final Rejection | Nobuo Tsukamoto |
| 17282774 | Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Immune Checkpoint Antagonist or Agonist | Non-Final OA | Bavarian Nordic A/S |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | Non-Final OA | Seagen Inc. |
| 18037219 | METHODS FOR TREATING INFLAMMATORY SKIN CONDITIONS | Non-Final OA | CSL INNOVATION PTY LTD |
| 18252081 | MADCAM TARGETED THERAPEUTICS AND USES THEREOF | Non-Final OA | PANDION OPERATIONS, INC. |
| 18053705 | ADOPTIVE CELL THERAPY COMBINATION TREATMENT AND COMPOSITIONS THEREOF | Non-Final OA | Immatics US, Inc. |
| 17298008 | HETERODIMERIC TETRAVALENCY AND SPECIFICITY ANTIBODY COMPOSITIONS AND USES THEREOF | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18025322 | USE OF CHIAURANIB IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN ANTITUMOR THERAPY | Non-Final OA | CHENGDU CHIPSCREEN PHARMACEUTICAL LTD. |
| 18024928 | COMBINATION COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | AUSTRAL UNIVERSITY |
| 18059548 | B7-H4 Antibodies and Anti-B7-H4 Antibody/IL-15 Fusion Proteins | Non-Final OA | Kadmon Corporation, LLC |
| 18054575 | ONCOLYTIC VIRUS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR FOR TREATING TUMORS | Non-Final OA | Joint Biosciences (SH) Ltd. |
| 17761946 | USE OF DKK-1 INHIBITORS FOR TREATING CANCER | Non-Final OA | Leap Therapeutics, Inc. |
| 17722182 | Methods of Isoprenoid Synthesis Using a Genetically Engineered Hydrocarbonoclastic Organism in a Biofilm Bioreactor | Non-Final OA | Capra Biosciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy